Feed FMS
FM

Fresenius Medical Care FMS · NYSE

$21.93 -1.08% (-$0.24)

Summary

60 / 100 · Bulios Score

What speaks for it

  • Earnings per share grew by 43% a year over the last 3 years.
  • The share price is below the Bulios Fair Price.
  • It bought back its own shares for 562.2M € in the last fiscal year, 5.4% of its market value.

What to watch

  • Revenue grew by only 0.4% a year over the last 3 years.
  • It earns only 5.7 EUR a year on every 100 EUR of invested capital.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $21.93
5-year average P/E 23.8 53% lower
P/E today 11.1
Medical - Care Facilities industry median
P/E today 11.1

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 11.1 EUR for 1 EUR of yearly profit. Over the last five years it was 23.8 EUR on average.

Valuation in detail

Is it growing?

Slowly

Revenue (EUR)

Diluted EPS (EUR)

  • Analyst estimate

Revenue grew by 1.9% a year over 5 years. Over the last 3 years it grew by 0.4% a year. For the next fiscal year analysts expect revenue to grow by 0.9%. Earnings per share grew by 43% a year over the last 3 years.

Growth in detail

Does it make money?

Reasonably

Where 100 EUR of revenue goes

Net profit, industry median (Medical - Care Facilities) 6.7 EUR

Out of every 100 EUR of revenue, 4.8 EUR is left as net profit.

Profitability in detail

Is it financially healthy?

Debt is a burden

Repaying all its debt would take 6.2 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

Moderate, safe
Yield
3.97%
Paid out of profit
44%
Raised in a row
2 years

You receive $0.87 per share a year. The company covers the payout with ease.

Dividends in detail

What do analysts expect?

Neutral

Today's price within the analysts' price targets

The average target of $23.67 is 7.9% above today's price. 24% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2025

By product

By region

Health Care Services brings in 75% of revenue. Health Care Products grew fastest, by 4.3% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.